Literature DB >> 18787386

Testosterone-related shortening of QTc interval in women with polycystic ovary syndrome.

B Vrtovec1, H Meden-Vrtovec, M Jensterle, B Radovancevic.   

Abstract

CONTEXT: The presence of several cardiovascular risk factors is observed in women with polycystic ovary syndrome (PCOS). On the other hand, the QTc interval duration, which is related to cardiac arrhythmia and sudden death, has not been investigated thoroughly in PCOS population.
OBJECTIVE: To investigate QTc interval duration and its relation to testosterone in women with PCOS.
DESIGN: Cross sectional case-control study.
SETTING: Outpatient setting, tertiary university medical centre. PATIENTS: We enrolled 119 consecutive patients in whom PCOS was diagnosed based on oligomenorrhea, infertility (>2 yr), ineffective ovarian stimulation, and ultrasonographic criteria. The control group (controls) included 64 age-matched healthy women without clinical or laboratory evidence of PCOS.
INTERVENTIONS: In all participants we measured QTc interval duration on a standard electrocardiogram and determined plasma levels of high sensitivity C-reactive protein (hsCRP), endothelin-1 (ET-1), insulin, and testosterone. MAIN OUTCOME MEASURE: Shorter QTc interval duration in PCOS patients.
RESULTS: When compared to controls, PCOS patients displayed higher values of hsCRP (2.35+/-2.14 mg/l vs 1.18+/-1.24 mg/l; p=0.01), ET-1 (23.6+/-10.3 ng/l vs 12.9+/-20.7 ng/l; p=0.03), insulin (18.5+/-7.8 mIU/l vs 10.7+/-9.1 mIU/l; p=0.02), and testosterone (2.7+/-2.1 nmol/l vs 1.4+/-1.7 nmol/l; p=0.01). QTc interval in PCOS patients was significantly shorter than in controls (401+/-61 msec vs 467+/-61 msec; p=0.007), and inversely related to the plasma levels of testosterone (Spearman -0.45, p=0.005).
CONCLUSIONS: QTc interval in PCOS patients is short, and inversely associated with increased levels of testosterone. QTc interval duration is not part of an adverse cardiac risk profile in PCOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787386     DOI: 10.1007/BF03345619

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  More light on QT interval measurement.

Authors:  L Toivonen
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  Nontranscriptional regulation of cardiac repolarization currents by testosterone.

Authors:  Chang-Xi Bai; Junko Kurokawa; Masaji Tamagawa; Haruaki Nakaya; Tetsushi Furukawa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

Review 3.  Polycystic ovary syndrome.

Authors:  David A Ehrmann
Journal:  N Engl J Med       Date:  2005-03-24       Impact factor: 91.245

4.  Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs.

Authors:  L Fülöp; T Bányász; G Szabó; I B Tóth; T Bíró; I Lôrincz; A Balogh; K Petô; I Mikó; P P Nánási
Journal:  Acta Physiol (Oxf)       Date:  2006 Nov-Dec       Impact factor: 6.311

5.  Inflammatory and endothelial markers in women with polycystic ovary syndrome.

Authors:  E Diamanti-Kandarakis; K Alexandraki; C Piperi; A Protogerou; I Katsikis; T Paterakis; J Lekakis; D Panidis
Journal:  Eur J Clin Invest       Date:  2006-10       Impact factor: 4.686

6.  Repolarization measures and their relation to sex hormones in postmenopausal women with cardiovascular disease receiving hormone replacement therapy.

Authors:  Karolina Nowinski; Ulla Pripp; Kjell Carlström; Britt-Marie Landgren; Karin Schenck-Gustafsson; Lennart Bergfeldt
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

7.  QT dispersion in patients with polycystic ovary syndrome.

Authors:  Mete Alpaslan; Ersel Onrat; Mehmet Yilmazer; Veysel Fenkci
Journal:  Jpn Heart J       Date:  2002-09

8.  Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.

Authors:  Andromachi Vryonidou; Athanasios Papatheodorou; Anna Tavridou; Thomais Terzi; Vasiliki Loi; Ioannis-Anastasios Vatalas; Nikolaos Batakis; Constantinos Phenekos; Amalia Dionyssiou-Asteriou
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

9.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.

Authors:  R R Makkar; B S Fromm; R T Steinman; M D Meissner; M H Lehmann
Journal:  JAMA       Date:  1993-12-01       Impact factor: 56.272

10.  QT interval prolongation predicts cardiovascular mortality in an apparently healthy population.

Authors:  E G Schouten; J M Dekker; P Meppelink; F J Kok; J P Vandenbroucke; J Pool
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

View more
  6 in total

1.  Short QT interval linked to androgen misuse: wider significance and possible basis.

Authors:  Jules C Hancox; Stéphanie C Choisy; Andrew F James
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

2.  Cardiac arrhythmias in women.

Authors:  Leila Ganjehei; Ali Massumi; Alireza Nazeri; Mehdi Razavi
Journal:  Tex Heart Inst J       Date:  2011

Review 3.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

Review 4.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

5.  Assessment of atrial electromechanical interval and P wave dispersion in patients with polycystic ovary syndrome.

Authors:  Pınar Türker Bayır; Ümit Güray; Serkan Duyuler; Burcu Demirkan; Oya Kayaalp; Selçuk Kanat; Yeşim Güray
Journal:  Anatol J Cardiol       Date:  2015-03-23       Impact factor: 1.596

Review 6.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.